Indivior Pharmaceuticals, Inc. · NASDAQ:INDV

Indivior Pharmaceuticals — Q2 2024 Earnings Presentation

12 slides from Indivior Pharmaceuticals's earnings presentation, Jul 25, 2024

  1. Slide 1: Q2 / H1 2024 Results

    Q2 / H1 2024 Results July 25, 2024

  2. Slide 2: Important Cautionary Statement Regarding Forward-looking Statements

    Q2/H1 2024 Results | July 25, 2024 Important Cautionary Statement Regarding Forward-looking Statements This presentation contains certain statements that are forward-looking. Forward-looking statements include, among other things, express and implied statements regarding: strategic priorities, strat

  3. Slide 3: Mark Crossley, Chief Executive Officer

    Mark Crossley Chief Executive Officer

  4. Slide 4: Q2 2024 Highlights

    Q2/H1 2024 Results | July 25, 2024 Q2 2024 Highlights1 TOTAL NR SUBLOCADE® NR REPORTED OP. PROFIT / ADJ. OP. PROFIT2 $299m, 8% $192m, 24% ($132m) / $79m, 11% Q2 2024 Key Messages: ➔ Results in line with July 9th Business Update ➔ Progress on legacy litigation – $75m provision for agreed amount of ex

  5. Slide 5: Executing Against our Strategic Priorities

    Q2/H1 2024 Results | July 25, 2024 Executing Against our Strategic Priorities Grow Diversify Build & Optimize SUBLOCADE Revenue Progress Operating >$1.5bn Pipeline4 Model • SUBLOCADE Q2 2024 NR of $192m, • SUBLOCADE ex-U.S. Q2 2024 NR • INDV-6001 (OUD5): Protocol for • $405m of gross cash and +24% v

  6. Slide 6: Ryan Preblick, Chief Financial Officer

    Ryan Preblick Chief Financial Officer

  7. Slide 7: Q2 2024 Financial Highlights

    Q2/H1 2024 Results | July 25, 2024 Q2 2024 Financial Highlights Key Takeaways: Operating Results: (vs. Q2 2023 unless otherwise indicated) (Reported and Adjusted1) $ mil Q2 24 Q2 23 Change ➤ Q2 2024 total NR growth of 8% Net Revenue (NR): 299 276 8% ▪ U.S. NR up 12% U.S. NR 254 226 12% ▪ ROW NR down

  8. Slide 8: Cash & Borrowing Position

    Q2/H1 2024 Results | July 25, 2024 Cash & Borrowing Position Cash & Borrowings: Key Takeaways: Cash & investments of $405m1 ➤ Scheduled settlement payments totaling $70m paid ($ in mil.) during H1 2024 June 30, 2024 Dec. 31, 2023 ➤ Approximately $70m used for share repurchases Cash & Cash Equivalent

  9. Slide 9: FY 2024 Guidance – Updated July 9th and Reiterated Today

    Q2/H1 2024 Results | July 25, 2024 FY 2024 Guidance – Updated July 9th and Reiterated Today Top-Line Assumptions: ($ in mil.) ➤ Underlying U.S. BMAT3 growth of mid- to high-single digits Total Net Revenue $1,150m to $1,215m (up 8% at mid-point) ➤ OPVEE NR inclusive of $8m from BARDA contract ➤ U.S.

  10. Slide 10: Appendix

    Appendix

  11. Slide 11: Investor Marketing – H2 2024

    Q2/H1 2024 Results | July 25, 2024 Investor Marketing – H2 2024 Date Key Event Sept. 4th – 6th Morgan Stanley Healthcare Conference (New York) Sept. 9th Jefferies “Back to School” Event (virtual) Late Oct. / Early Nov. Q3 24 Results Earnings Call & Investor Roadshow Nov. 18th – 19th Stifel Healthcar

  12. Slide 12: Financial Reconciliations

    Q2/H1 2024 Results | July 25, 2024 Financial Reconciliations Reconciliation of gross profit to adjusted gross profit Q2 Q2 H1 H1 2024 2023 2024 2023 For the three and six months ended June 30 $m $m $m $m Gross profit 206 226 444 440 Exceptional items and other adjustments in cost of sales 44 2 47 2

Indivior Pharmaceuticals — Q2 2024 Earnings Presentation on 6ix